Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dalcotidine (KU 1257) 是一种新型组胺H2受体拮抗剂,具有组胺H9受体拮抗活性和抗分泌作用,与豚鼠大脑皮层结合的Ki 值为0.040 对分离性豚鼠右心房组胺诱导的正变时反应的拮抗作用的KB 值为0.041。Dalcotidine 提高了溃疡愈合的质量,可能有助于降低溃疡的复发率和复发率。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,010 | 现货 | ||
5 mg | ¥ 2,490 | 现货 | ||
10 mg | ¥ 3,720 | 现货 | ||
25 mg | ¥ 5,990 | 现货 | ||
50 mg | ¥ 8,290 | 现货 | ||
100 mg | ¥ 10,900 | 现货 | ||
500 mg | ¥ 22,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,360 | 现货 |
产品描述 | Dalcotidine (KU 1257) is a novel histamine H2 receptor antagonist with histamine H9 receptor antagonistic activity and antisecretory effects.The Ki value for binding to guinea pig cerebral cortex was 0.040 The KB value for antagonism of histamine-induced positive chronotropic responses in the right atrium of isolate guinea pigs was 0.041.Dalcotidine improves the quality of ulcer healing, and may contribute to a reduction in ulcer recurrence and relapse rates. |
靶点活性 | H2 receptor:0.04 mumol/l |
体内活性 | KU-1257 (10-50 mg/kg x 2/day; oral; rats)markedly promoted the well-balanced healing of gastric ulcers, as evidenced by the reduction of ulcers, regeneration of mucosa and proliferation of connective tissue. KU-1257 caused an increase in gastric mucus secretion in the regenerated mucosa around the gastric ulcers. KU-1257 is characterized by a potent promoting action on the healing of chronic ulcers, suggesting that the increase in gastric mucus secretion might be associated with the antiulcer actions of KU-1257 in part.[2] |
别名 | KU 1257, KU-1257 |
分子量 | 319.44 |
分子式 | C18H29N3O2 |
CAS No. | 120958-90-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.6 mg/mL (11.27 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1305 mL | 15.6524 mL | 31.3048 mL | 78.262 mL |
5 mM | 0.6261 mL | 3.1305 mL | 6.261 mL | 15.6524 mL | |
10 mM | 0.313 mL | 1.5652 mL | 3.1305 mL | 7.8262 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dalcotidine 120958-90-9 GPCR/G Protein Immunology/Inflammation Neuroscience Histamine Receptor KU 1257 KU-1257 KU1257 Inhibitor inhibitor inhibit